Samantha C Sodergren1, Ellen Copson2, Alice White2, Fabio Efficace3, Mirjam Sprangers4, Deborah Fitzsimmons5, Andrew Bottomley6, Colin D Johnson2. 1. Cancer Sciences, University of Southampton, Southampton, SO16 6YD, UK. S.C.Sodergren@soton.ac.uk. 2. Cancer Sciences, University of Southampton, Southampton, SO16 6YD, UK. 3. Health Outcomes Research Unit, Gimema, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy. 4. Department of Medical Psychology, University of Amsterdam, Amsterdam, The Netherlands. 5. Swansea Centre for Health Economics, Swansea University, Swansea, SA2 8PP, UK. 6. European Organisation for Research and Treatment of Cancer Quality of Life Department, 1200, Brussels, Belgium.
Abstract
PURPOSE: Targeted therapies (TTs), notably trastuzumab, have improved outcomes for breast cancer characterised by overexpression of human epidermal growth factor receptors including HER2. Compared with chemotherapy treatments, TTs are more specific in their targets and are delivered over longer periods of time, thus presenting different side-effect profiles. The objective of this paper is to systematically review and describe the side effects associated with TTs used in the adjuvant and metastatic settings for HER2+ breast cancer. METHODS: The MEDLINE, EMBASE, CINAHL, Web of Science and Cochrane Library databases were searched from January 2007 to March 2015 to identify clinical trials and prospective studies reporting toxicities associated with TTs (mainly trastuzumab and lapatinib) used without other therapies in the treatment of HER2-positive breast cancer. Two independent reviewers selected papers based on their titles and abstracts. All papers selected by either reviewer were included. A third reviewer extracted and tabulated the relevant data using a data extraction form. RESULTS: We identified 5478 papers, of which 299 were reviewed and 18 trials identified involving 6980 patients. A total of 66 side effects were identified, including 46 "patient-based" symptoms and 20 "medically defined" outcomes. Side effects were more common for patients treated with therapies other than trastuzumab or with dual-HER2 regimens and for patients with metastatic disease. Diarrhoea and skin rash were the most prevalent symptoms, experienced by 29 % and 22 % of patients overall, respectively. There were 119 (2 %) cardiac events reported, and these were not exclusive to trastuzumab-treated patients. The majority of side effects (n = 52) were experienced by 1 % or less of patients and were predominantly of grade 1/2 toxicity. CONCLUSIONS: This systematic review provides a detailed analysis of side effects of HER2+ therapies in a large number of patients included in trials, enabling an accurate estimate of prevalence and a complete understanding of the patients' experience. This will help clinicians and patients in treatment planning.
PURPOSE: Targeted therapies (TTs), notably trastuzumab, have improved outcomes for breast cancer characterised by overexpression of human epidermal growth factor receptors including HER2. Compared with chemotherapy treatments, TTs are more specific in their targets and are delivered over longer periods of time, thus presenting different side-effect profiles. The objective of this paper is to systematically review and describe the side effects associated with TTs used in the adjuvant and metastatic settings for HER2+ breast cancer. METHODS: The MEDLINE, EMBASE, CINAHL, Web of Science and Cochrane Library databases were searched from January 2007 to March 2015 to identify clinical trials and prospective studies reporting toxicities associated with TTs (mainly trastuzumab and lapatinib) used without other therapies in the treatment of HER2-positive breast cancer. Two independent reviewers selected papers based on their titles and abstracts. All papers selected by either reviewer were included. A third reviewer extracted and tabulated the relevant data using a data extraction form. RESULTS: We identified 5478 papers, of which 299 were reviewed and 18 trials identified involving 6980 patients. A total of 66 side effects were identified, including 46 "patient-based" symptoms and 20 "medically defined" outcomes. Side effects were more common for patients treated with therapies other than trastuzumab or with dual-HER2 regimens and for patients with metastatic disease. Diarrhoea and skin rash were the most prevalent symptoms, experienced by 29 % and 22 % of patients overall, respectively. There were 119 (2 %) cardiac events reported, and these were not exclusive to trastuzumab-treated patients. The majority of side effects (n = 52) were experienced by 1 % or less of patients and were predominantly of grade 1/2 toxicity. CONCLUSIONS: This systematic review provides a detailed analysis of side effects of HER2+ therapies in a large number of patients included in trials, enabling an accurate estimate of prevalence and a complete understanding of the patients' experience. This will help clinicians and patients in treatment planning.
Authors: Marion Procter; Thomas M Suter; Evandro de Azambuja; Urania Dafni; Veerle van Dooren; Susanne Muehlbauer; Miguel Angel Climent; Ernst Rechberger; Walter Tsang-Wu Liu; Mazakasu Toi; R Charles Coombes; David Dodwell; Olivia Pagani; Jorge Madrid; Marcia Hall; Shin-Cheh Chen; Christian Focan; Michael Muschol; Dirk J van Veldhuisen; Martine J Piccart-Gebhart Journal: J Clin Oncol Date: 2010-06-07 Impact factor: 44.544
Authors: Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyereislova; Mitch Dowsett; Aron Goldhirsch; Michael Untch; Gabriella Mariani; Jose Baselga; Manfred Kaufmann; David Cameron; Richard Bell; Jonas Bergh; Robert Coleman; Andrew Wardley; Nadia Harbeck; Roberto I Lopez; Peter Mallmann; Karen Gelmon; Nicholas Wilcken; Erik Wist; Pedro Sánchez Rovira; Martine J Piccart-Gebhart Journal: Lancet Date: 2007-01-06 Impact factor: 79.321
Authors: Miguel Martin; Jacques Bonneterre; Charles E Geyer; Yoshinori Ito; Jungsil Ro; Istvan Lang; Sung-Bae Kim; Caroline Germa; Jennifer Vermette; Kenneth Wang; Kongming Wang; Ahmad Awada Journal: Eur J Cancer Date: 2013-08-15 Impact factor: 9.162
Authors: Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: José Baselga; Karen A Gelmon; Shailendra Verma; Andrew Wardley; Pierfranco Conte; David Miles; Giulia Bianchi; Javier Cortes; Virginia A McNally; Graham A Ross; Pierre Fumoleau; Luca Gianni Journal: J Clin Oncol Date: 2010-02-01 Impact factor: 44.544
Authors: Henry M Kuerer; Aman U Buzdar; Elizabeth A Mittendorf; Francisco J Esteva; Anthony Lucci; Luis M Vence; Laszlo Radvanyi; Funda Meric-Bernstam; Kelly K Hunt; William Fraser Symmans Journal: Cancer Date: 2010-08-24 Impact factor: 6.860
Authors: Samantha C Sodergren; Alice White; Fabio Efficace; Mirjam Sprangers; Deborah Fitzsimmons; Andrew Bottomley; Colin D Johnson Journal: Crit Rev Oncol Hematol Date: 2014-01-17 Impact factor: 6.312
Authors: M E Lacouture; S M Laabs; M Koehler; R W Sweetman; A J Preston; A Di Leo; H L Gomez; V M Salazar; J A Byrne; K M Koch; K L Blackwell Journal: Breast Cancer Res Treat Date: 2008-07-04 Impact factor: 4.872
Authors: Xavier Pivot; Gilles Romieu; Marc Debled; Jean-Yves Pierga; Pierre Kerbrat; Thomas Bachelot; Alain Lortholary; Marc Espié; Pierre Fumoleau; Daniel Serin; Jean-Philippe Jacquin; Christelle Jouannaud; Maria Rios; Sophie Abadie-Lacourtoisie; Nicole Tubiana-Mathieu; Laurent Cany; Stéphanie Catala; David Khayat; Iris Pauporté; Andrew Kramar Journal: Lancet Oncol Date: 2013-06-11 Impact factor: 41.316
Authors: Danielle D Jandial; Lauren S Krill; Lixia Chen; Chunli Wu; Yu Ke; Jun Xie; Bang H Hoang; Xiaolin Zi Journal: Molecules Date: 2017-03-14 Impact factor: 4.411
Authors: Konstantinos V Floros; Sheeba Jacob; Richard Kurupi; Carter K Fairchild; Bin Hu; Madhavi Puchalapalli; Jennifer E Koblinski; Mikhail G Dozmorov; Sosipatros A Boikos; Maurizio Scaltriti; Anthony C Faber Journal: Cell Death Dis Date: 2021-02-15 Impact factor: 8.469